AVANIR PHARMACEUTICALS for AVANIR PHARMACEUTICALS
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE DRATZ FERGUSON New | — |
Medical/Disease Research/Clinical Labs MED
Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE DRATZ FERGUSON New | — |
Veterans VET
Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE DRATZ FERGUSON New | — |
Medicare/Medicaid MMM
Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE DRATZ FERGUSON New | — |
Budget/Appropriations BUD
Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE DRATZ FERGUSON New | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| OTSUKA PHARMACEUTICAL CO., LTD. | Japan | Japan | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.